BCLI Director Jacob A. Frenkel Receives 100,000 RSU Award

What Happened

• Jacob A. Frenkel, a director of BrainStorm Cell Therapeutics, was granted 100,000 restricted stock units (RSUs) on July 24, 2026. The award was granted at $0.00 per share (no cash paid), so the reported acquisition value is $0.
• The RSUs vest in two installments: 50% on October 24, 2026 and the remaining 50% on April 24, 2027, subject to continued service under a Consulting Agreement dated July 24, 2026.

Key Details

• Transaction date: July 24, 2026; Filing date: July 28, 2026.
• Price: $0.00 per share; Shares granted: 100,000; Reported acquisition value: $0.
• Shares owned after transaction: not specified in this Form 4.
• Footnote: RSUs issued under the issuer’s 2014 Global Share Option Plan and governed by the Consulting Agreement; vesting contingent on continued service.
• Filing timeliness: the Form 4 was filed four days after the transaction date — investors may note the filing and verify timeliness against SEC Form 4 deadlines.

Context

• This was an equity award (grant of RSUs), not an open‑market purchase or sale. RSUs generally convert into shares only after vesting and typically reflect compensation for service rather than a direct market investment by the insider.
• Such grants are routine for compensating directors/consultants and do not by themselves indicate a personal buying or selling decision.